Bristol Myers Squibb Announces RELATIVITY-047, a Trial Evaluating Anti-LAG-3 Antibody Relatlimab and Opdivo in Patients with Previously Untreated Metastatic or Unresectable Melanoma, Meets Primary Endpoint of Progression-Free Survival Biotech Investing
Real-World Evidence Supports Effectiveness of First-line IBRANCE® Combination Therapy in HR+, HER2- Metastatic Breast Cancer Pharmaceutical Investing
ALERT FROM FIRM THAT FILED THE LAWSUIT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against BELLUS Health Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Biotech Investing
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Bellus Health, Neptune Wellness, Sequential Brands, and CytoDyn and Encourages Investors to Contact the Firm Biotech Investing
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against BELLUS Health Inc. Biotech Investing
Myovant Sciences and Pfizer Announce Positive Data from Phase 3 LIBERTY Randomized Withdrawal Study of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids Pharmaceutical Investing
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of BELLUS Health Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 17, 2021 - BLU Biotech Investing
BLU INVESTOR NOTICE: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages BELLUS Health Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - BLU Biotech Investing
Seegnal Inc. Receives Gold Mark from the Standards Institution of Israel, Advancing Commercialization Readiness
